Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Sarepta Therapeutics faces increased scrutiny after a second fatal case of acute liver failure linked to its Duchenne muscular dystrophy gene therapy, Elevidys, prompting William Blair to highlight investor hesitancy due to uncertainty surrounding the number of non-ambulatory patients at risk. Consequently, an analyst downgraded Sarepta from Outperform to Market Perform, citing concerns over reduced peak revenue potential due to potentially limited penetration in the non-ambulatory population and the emergence of competing gene therapies with potentially safer profiles; SRPT shares are down 3.18%.

Analysis

Sarepta Therapeutics is facing a significant setback following a second reported fatality due to acute liver failure linked to its Duchenne muscular dystrophy gene therapy, Elevidys. This event has prompted an immediate market reaction, with the stock falling 3.18%, and a ratings downgrade from William Blair to Market Perform from Outperform. The core of the issue lies in the heightened uncertainty surrounding the drug's safety profile, particularly for non-ambulatory patients. This uncertainty directly impacts financial projections, as the non-ambulatory segment was a key component of prior peak revenue estimates, which are now considered less achievable. The situation is further complicated by the looming threat of competition, with rival therapies like Solid Biosciences' SGT-003 potentially entering the market by 2027 with what early data suggests could be a safer profile. While William Blair notes continued interest in Elevidys for ambulatory patients, the combination of reduced revenue opportunity and unresolved safety variables is expected to be a major deterrent for investors in the near term.

Key Decisions for Investors

• Given the downgrade and material uncertainty surrounding future revenue from the non-ambulatory patient segment, investors should reassess exposure to Sarepta, as the stock's risk profile has significantly increased.
• Closely monitor any further safety updates from the company, as another adverse event would likely trigger further downside and validate concerns about Elevidys' long-term viability.
• It is prudent to track the clinical development of competitors like Solid Biosciences (SLDB), as their progress with potentially safer alternatives now poses a more direct threat to Elevidys' future market share.